Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 3

Tests semaglutide after clot removal in adults with a large-vessel stroke

Tests semaglutide injection with clot removal in adults with acute large vessel stroke.

Key facts

Who runs it
Wei Hu
Where
Hefei, ChinaSee the site
Trial code
Registry title
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
Status
Not yet recruiting
Phase
Phase 3
People taking part
390 people, planned
Started
Feb 2025
Expected to end
Feb 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Semaglutide 0.5 mg
  • Standard medical treatment
Record updated
23 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a sudden stroke caused by a blocked large brain artery who are having a procedure to remove the clot. It tests whether semaglutide helps recovery.

Age
18 years or older
Sex
All sexes
Disease stage
Stroke from a blocked large brain artery (terminal ICA, M1 or dominant M2), within 24 hours of last known well. NIHSS of 6 or more. ASPECTS of 6 or more if within 6 hours. Salvageable brain tissue on CT perfusion or MRI if 6 to 24 hours.
Earlier treatment
Must not have received clot-dissolving drugs into a vein (alteplase or tenecteplase). Must be having endovascular treatment (a procedure to remove the clot).

Main reasons for not taking part

  • Bleeding in the brain or a brain tumour on first imaging
  • Pregnant or breastfeeding
  • Allergy or other reason that rules out GLP-1RA drugs, such as thyroid or pancreatic cancer history or proliferative diabetic retinopathy
  • Severe kidney or liver disease, or blood glucose, platelet count or INR outside the set limits
  • Taking part in another clinical trial

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • LVO stroke at terminal ICA, M1 or dominant M2 with an LKW-to-randomization ≤24 hours
  • Age ≥ 18 years old
  • National Institute of Health Stroke Scale ≥ 6 at the time of brain imaging
  • Acute LVO stroke due to thromboembolism or intracranial stenosis
  • Patients who received computer tomographic or magnetic resonance angiography
  • ASPECTS ≥ 6 for patients with LKW-to-randomization ≤6 hours
  • Salvageable ischemic penumbra demonstrated by CT perfusion or MRI for patients with LKW-to-randomization between 6 and 24 hours
  • Informed consent obtained from patient or acceptable patient surrogate

Who cannot take part

  • Use of intravenous thrombolytic therapy (alteplase or tenecteplase)
  • Systolic blood pressure >185mmHg or diastolic blood pressure >110mmHg that cannot be controlled by antihypertensive drugs
  • Intracranial hemorrhage or brain tumour on initial imaging (except small meningiomas)
  • Severe comorbid illness, e.g. terminal malignancy with life expectancy <1 year
  • Contraindications to GLP1-RA, including history of allergy to GLP-1RA, family or personal history of multiple endocrine neoplasia, medullary thyroid or pancreatic carcinoma, or proliferative diabetic retinopathy
  • Blood glucose <2.7 or > 22.2 mmol/L; platelet count <50x10\^9 /L; INR >1.7
  • Patients with known estimated glomerular filtration rate of <30ml/min/1.73m2 or creatinine >3mg/dL (265.2µmol/L); chronic liver disease with Child's Pugh score C or above; or recurrent unexplained hypoglycemia
  • Pre-stroke mRS > 2 for patients <80 years and > 1 for patients ≥ 80 years old
  • Simultaneous occlusion of bilateral anterior circulation, or both anterior and posterior circulation
  • Unstable hemodynamics on presentation that require resuscitation
  • Pregnant or lactating female
  • Participation in another clinical trial
  • Suspected or confirmed vasculitis of the central nervous system
  • Unable to complete 90-day follow-up assessment

Where in China

  • The First Affiliated Hospital of University of Science and Technology of ChinaHefei, ChinaContact: Wei Hu, MD,PhDNo longer taking part

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if semaglutide works to treat acute ischemic stroke (AIS). It will also learn about the safety of semaglutide in AIS. The main question it aims to answer is: Does semaglutide improve the 90-days functional outcome in participants with acute large vessel occlusion who receive the endovascular treatment (EVT)? Researchers will compare semaglutide injection to non-injection to see if semaglutide works to improve the functional outcome in participants with EVT.

Read full original descriptionShow less

Participants will:

* Receive 0.5mg semaglutide injection before (Day 0) and 1 week (Day 7) after EVT , or EVT alone. * Have additional blood test before and after EVT. * Receive neurological assessment before EVT, Day 1, Day 3, Day 5-7 after EVT or on hospital discharge (whichever earlier), Day 90±14 after EVT. Audio or video of the assessment may be recorded if possible. * Receive brain CT + CT angiogram + CT perfusion and MRI after EVT, where the CT scan may be repetitive.

The 2 groups in the trial

  • semaglutideTreatment being tested

    Participants will receive 0.5mg semaglutide injection before (Day 0) and 1 week (Day 7) after EVT. Additionally, they will receive antiplatelet drugs, anticoagulation or combinations of these treatment modality according to national and institutional guidelines.

    Treatment: Semaglutide 0.5 mg and Standard medical treatment

  • Standard medical managementPlacebo, for comparison

    Standard medical management. Participants will receive EVT, antiplatelet drugs, anticoagulation or combinations of these treatment modality according to national and institutional guidelines.

    Treatment: Standard medical treatment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
Plain-language title
Tests semaglutide after clot removal in adults with a large-vessel strokeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
23 January 2025